Heilongjiang ZBD Pharmaceutical Management
Management criteria checks 3/4
Heilongjiang ZBD Pharmaceutical's CEO is Jiujiang Yan, appointed in Jul 2022, has a tenure of 2.42 years. directly owns 0.016% of the company’s shares, worth CN¥1.80M. The average tenure of the management team and the board of directors is 2.4 years and 5.4 years respectively.
Key information
Jiujiang Yan
Chief executive officer
CN¥1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.4yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
We Like The Quality Of Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings
Nov 05
Getting In Cheap On Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Is Unlikely
Oct 18Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly
Sep 26Does Heilongjiang ZBD Pharmaceutical (SHSE:603567) Have A Healthy Balance Sheet?
May 28Why Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings Are Better Than They Seem
May 06Insufficient Growth At Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Hampers Share Price
Apr 17CEO
Jiujiang Yan (46 yo)
2.4yrs
Tenure
CN¥1,170,500
Compensation
Mr. Jiujiang Yan serves as Director of Heilongjiang ZBD Pharmaceutical Co., Ltd. since October 2019 and erves as its General Manager since July 2022 and served as its Deputy General Manager since August 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 2.4yrs | CN¥1.17m | 0.016% CN¥ 1.8m | |
| CFO & Accounting Supervisor | 5.3yrs | CN¥694.20k | 0.016% CN¥ 1.8m | |
| Board Secretary | 1.7yrs | CN¥290.50k | 0.011% CN¥ 1.2m | |
| Deputy General Manager | 2.6yrs | CN¥452.40k | 0.011% CN¥ 1.2m | |
| Deputy General Manager | 1.6yrs | CN¥204.20k | 0.011% CN¥ 1.2m |
2.4yrs
Average Tenure
44yo
Average Age
Experienced Management: 603567's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5.2yrs | CN¥1.17m | 0.016% CN¥ 1.8m | |
| Chairman of the Board | 13.8yrs | CN¥2.69m | no data | |
| Chairman of the Supervisory Board | 10.8yrs | no data | no data | |
| Supervisor | 13.8yrs | no data | 0.000060% CN¥ 6.6k | |
| Independent Director | 3.6yrs | CN¥80.00k | no data | |
| Independent Director | 1.6yrs | CN¥49.20k | no data | |
| Director | 5.6yrs | CN¥80.00k | no data | |
| Employee Supervisor | 1.8yrs | no data | no data |
5.4yrs
Average Tenure
51yo
Average Age
Experienced Board: 603567's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 10:05 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Heilongjiang ZBD Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |